Aradigm Corporation (OTCBB:ARDM) has announced that the European Medicines Agency (EMEA) granted Orphan Drug Designation to the Company’s inhaled liposomal ciprofloxacin drug product candidate for the treatment of lung infections associated with cystic fibrosis (“CF”).
Under European guidelines, Orphan Medicinal Product Designation provides 10 years of potential market exclusivity if the product candidate is the first product candidate for the indication approved for marketing in the European Union. Orphan drug designation also allows the candidate's sponsor to seek assistance from the EMEA in optimizing the candidate's clinical development through participation in designing the clinical protocol and preparing the marketing application. Additionally, a drug candidate designated by the Commission as an Orphan Medicinal Product may qualify for a reduction in regulatory fees as well as a European Union-funded research grant.
“We are very pleased that the EMEA granted our liposomal ciprofloxacin Orphan Drug Designation for the treatment of cystic fibrosis,” said Dr. Igor Gonda, the Company’s CEO and President. “This designation is an important step in our development of a new chronic treatment for management of respiratory infections commonly experienced by CF patients. Our once-a-day dosing has the potential to significantly decrease the burden of therapy for these patients.”
Ciprofloxacin is a widely prescribed antibiotic in the form of oral and intravenous formulations to treat acute exacerbations of infections of the lung frequently experienced by cystic fibrosis patients. It is often preferred because of its broad-spectrum anti-bacterial action. The Company’s once-a-day novel inhaled formulation of ciprofloxacin delivered in liposomes is to be used for chronic maintenance therapy as it is expected to achieve high antibiotic concentration for efficacy at the site of infection and relatively low systemic antibiotic concentrations to minimize side-effects.